Smoking and schizophrenia
Publication
, Journal Article
McEvoy, JP; Lindgren, J
Published in: Drug Development Research
1996
Patients with schizophrenia smoke at a higher prevalence rate (80%) than the general population (30%). Those patients with schizophrenia who smoke have an earlier age of onset and may have more refractory psychopathology. Smoking improves sensory gating, sustained attention, and cognitive performance in patients with schizophrenia. Conventional antipsychotic drugs initially increase smoking. Switching to the atypical antipsychotic, clozapine, decreases smoking. Smoking decreases the bioavailability of many antipsychotic drugs.
Duke Scholars
Published In
Drug Development Research
DOI
ISSN
0272-4391
Publication Date
1996
Volume
38
Issue
3-4
Start / End Page
263 / 266
Related Subject Headings
- Pharmacology & Pharmacy
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
McEvoy, J. P., & Lindgren, J. (1996). Smoking and schizophrenia. Drug Development Research, 38(3–4), 263–266. https://doi.org/10.1002/(SICI)1098-2299(199607/08)38:3/4<263::AID-DDR15>3.0.CO;2-#
McEvoy, J. P., and J. Lindgren. “Smoking and schizophrenia.” Drug Development Research 38, no. 3–4 (1996): 263–66. https://doi.org/10.1002/(SICI)1098-2299(199607/08)38:3/4<263::AID-DDR15>3.0.CO;2-#.
McEvoy JP, Lindgren J. Smoking and schizophrenia. Drug Development Research. 1996;38(3–4):263–6.
McEvoy, J. P., and J. Lindgren. “Smoking and schizophrenia.” Drug Development Research, vol. 38, no. 3–4, 1996, pp. 263–66. Scival, doi:10.1002/(SICI)1098-2299(199607/08)38:3/4<263::AID-DDR15>3.0.CO;2-#.
McEvoy JP, Lindgren J. Smoking and schizophrenia. Drug Development Research. 1996;38(3–4):263–266.
Published In
Drug Development Research
DOI
ISSN
0272-4391
Publication Date
1996
Volume
38
Issue
3-4
Start / End Page
263 / 266
Related Subject Headings
- Pharmacology & Pharmacy
- 1115 Pharmacology and Pharmaceutical Sciences